PTAB Litigation Blog
  • Home
  • Cookie Policy
  • About
  • Advanced Topics
  • Contributors
  • Contacts
  • Design Patents
  • Discovery
  • District Court
  • Joinder
Select Page
Sen. Hatch Introduces Hatch-Waxman Integrity Act

Sen. Hatch Introduces Hatch-Waxman Integrity Act

by Matthew Johnson | Dec 24, 2018 | Pharmaceutical, PTAB News

Sen. Orrin Hatch has introduced a bill that would augment the Hatch-Waxman Act, limiting challengers ability to proceed with patent challenges both in court and at the PTAB. Following is the introduction of the “Hatch-Waxman Integrity Act of 2018.” The...
Revised Standard Operating Procedure 2 and the New Path to PTAB Precedent

Revised Standard Operating Procedure 2 and the New Path to PTAB Precedent

by Doug Pearson | Oct 31, 2018 | Pharmaceutical, PTAB News, PTAB Trial Basics

By Doug Pearson Prior to the USPTO’s issuance of revised Standard Operating Procedure (SOP) 2 on September 20, 2018 (available here), designation of Board decisions as Precedential or Informative required, among other things, nomination of a decision to the Chief...
USPTO’s Revised SOP Sheds Light on Selection of PTAB Panels

USPTO’s Revised SOP Sheds Light on Selection of PTAB Panels

by Matthew Johnson | Oct 30, 2018 | Pharmaceutical, PTAB News, PTAB Trial Basics

By Josh Nightingale and Matt Johnson The USPTO has revised its standard operating procedure (SOP) governing the assignment of judges to panels in Patent Trial and Appeal Board (PTAB) cases.  The SOP, available here, provides guidance to Board administrative personnel...
PTAB Grants Rare Motion for Additional Discovery

PTAB Grants Rare Motion for Additional Discovery

by Gasper LaRosa | Aug 22, 2018 | Evidentiary Issues, Motions Practice, Pharmaceutical

By: Mital B. Patel and Gasper J. LaRosa The PTAB recently granted a rare motion for additional discovery into the question of whether an unnamed party, Amneal Pharmaceuticals, LLC (“Amneal”), should have been named as a real-party-in-interest.  In Kashiv LLC v. Purdue...
Federal Circuit: “All the Expenses” Does Not Mean “Attorneys’ Fees”

Federal Circuit: “All the Expenses” Does Not Mean “Attorneys’ Fees”

by Greg Castanias | Jul 31, 2018 | Federal Circuit Appeal, Pharmaceutical

By: Gregory A. Castanias Last Friday, the Federal Circuit issued its en banc opinion in NantKwest, Inc. v. Iancu, No. 16-1794 (Fed. Cir. July 27, 2018).  The Court held, by a 7-4 vote (Judge Chen, the former PTO Solicitor, was recused), that if the PTAB rejects a...
Sen. Hatch on Amendment to Incentivize Generic Drug Development

Sen. Hatch on Amendment to Incentivize Generic Drug Development

by Matthew Johnson | Jul 30, 2018 | Pharmaceutical

As we reported in our July 2, 2018 article Hatch Bill: Restore Hatch-Waxman Balance; Limit Generics’ Access to PTAB, Senator Orrin Hatch (R-Utah), the namesake and coauthor of the Hatch-Waxman Act, proposed (but has not yet introduced) an amendment titled the...
« Older Entries
Next Entries »

About this blog

Follow us on Twitter

Categories

  • 325(d) issues
  • Amendment Practice
  • CBMs
  • Claim Construction
  • Design Patents
  • Discovery
  • District Court
  • Estoppel
  • Evidentiary Issues
  • Expert Witnesses
  • Federal Circuit
  • Federal Circuit Appeal
  • Final Written Decisions
  • Joinder
  • Motions Practice
  • Other News
  • Patent Eligible Subject Matter
  • Petitions
  • PGR
  • Pharmaceutical
  • Preliminary Responses
  • Prior Art Issues
  • PTAB News
  • PTAB Trial Basics
  • Real Party in Interest
  • Request for Reconsideration
  • Standing
  • Stay
  • Time Limits
  • Trial Institution
  • Uncategorized

Archives

Links

www.jonesday.com

About Jones Day's Intellectual Property Practice

Subscribe to Jones Day publications

  • Privacy
  • Facebook
  • Twitter
  • RSS

The opinions expressed are those of the authors and do not necessarily reflect the views of Jones Day or its clients. The posts and information provided are for general information purposes and are not intended to be and should not be taken as legal advice.